Movement Alert｜Keymed Biosciences Intraday Rise 5.65%, AbbVie Billion-Dollar Apogee Acquisition Continues to Catalyze Long-Acting AD Pipeline

Market Focus06-26

On June 26, Keymed Biosciences rose 5.65% in regular trading, trading at HK$65.15/share, with turnover of HK$80.80 million.

On the news front, AbbVie's announced acquisition of Apogee for approximately US$10.9 billion continues to catalyze stocks in the long-acting atopic dermatitis space. Apogee's core asset is APG777, a long-acting IL-13 monoclonal antibody. The deal reflects multinational pharma's strong endorsement of strategic value and peak sales potential for long-acting AD assets. Keymed's CM512 belongs to the same long-acting AD track, and its market competitiveness could be significantly enhanced if clinical data supports extended dosing intervals.

Guojin Securities maintains a Buy rating on Keymed, noting that long-acting AD product value has been further validated by multinational pharmaceutical companies. Beyond the CM512 catalyst, the company recently received a US$257 million upfront payment from Gilead's acquisition of Ouro Medicines and a US$45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, strengthening its financial position.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1116975407?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 10:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1116975407","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Keymed Biosciences Intraday Rise 5.65%, AbbVie Billion-Dollar Apogee Acquisition Continues to Catalyze Long-Acting AD Pipeline","media":"Market Focus","content":"<p><p>On June 26, Keymed Biosciences rose 5.65% in regular trading, trading at HK$65.15/share, with turnover of HK$80.80 million.</p><p>On the news front, AbbVie's announced acquisition of Apogee for approximately US$10.9 billion continues to catalyze stocks in the long-acting atopic dermatitis space. Apogee's core asset is APG777, a long-acting IL-13 monoclonal antibody. The deal reflects multinational pharma's strong endorsement of strategic value and peak sales potential for long-acting AD assets. Keymed's CM512 belongs to the same long-acting AD track, and its market competitiveness could be significantly enhanced if clinical data supports extended dosing intervals.</p><p>Guojin Securities maintains a Buy rating on Keymed, noting that long-acting AD product value has been further validated by multinational pharmaceutical companies. Beyond the CM512 catalyst, the company recently received a US$257 million upfront payment from Gilead's acquisition of Ouro Medicines and a US$45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, strengthening its financial position.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Keymed Biosciences Intraday Rise 5.65%, AbbVie Billion-Dollar Apogee Acquisition Continues to Catalyze Long-Acting AD Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Keymed Biosciences Intraday Rise 5.65%, AbbVie Billion-Dollar Apogee Acquisition Continues to Catalyze Long-Acting AD Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 10:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Keymed Biosciences rose 5.65% in regular trading, trading at HK$65.15/share, with turnover of HK$80.80 million.</p><p>On the news front, AbbVie's announced acquisition of Apogee for approximately US$10.9 billion continues to catalyze stocks in the long-acting atopic dermatitis space. Apogee's core asset is APG777, a long-acting IL-13 monoclonal antibody. The deal reflects multinational pharma's strong endorsement of strategic value and peak sales potential for long-acting AD assets. Keymed's CM512 belongs to the same long-acting AD track, and its market competitiveness could be significantly enhanced if clinical data supports extended dosing intervals.</p><p>Guojin Securities maintains a Buy rating on Keymed, noting that long-acting AD product value has been further validated by multinational pharmaceutical companies. Beyond the CM512 catalyst, the company recently received a US$257 million upfront payment from Gilead's acquisition of Ouro Medicines and a US$45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, strengthening its financial position.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"","article_id":"1116975407","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1116975407","pubTimestamp":1782439771,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Keymed Biosciences rose 5.65% in regular trading, trading at HK$65.15/share, with turnover of HK$80.80 million.On the news front, AbbVie's announced acquisition of Apogee for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"动感快讯|科亚医药盘中涨5.65%艾伯维亿美元收购Apogee持续催化长效AD管线","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1},"content_text":"On June 26, Keymed Biosciences rose 5.65% in regular trading, trading at HK$65.15/share, with turnover of HK$80.80 million.On the news front, AbbVie's announced acquisition of Apogee for approximately US$10.9 billion continues to catalyze stocks in the long-acting atopic dermatitis space. Apogee's core asset is APG777, a long-acting IL-13 monoclonal antibody. The deal reflects multinational pharma's strong endorsement of strategic value and peak sales potential for long-acting AD assets. Keymed's CM512 belongs to the same long-acting AD track, and its market competitiveness could be significantly enhanced if clinical data supports extended dosing intervals.Guojin Securities maintains a Buy rating on Keymed, noting that long-acting AD product value has been further validated by multinational pharmaceutical companies. Beyond the CM512 catalyst, the company recently received a US$257 million upfront payment from Gilead's acquisition of Ouro Medicines and a US$45 million milestone payment from AstraZeneca for CMG901's Phase 3 initiation, strengthening its financial position.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.0","shortVersion":"4.45.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1116975407","isCrawlerRequest":true}